Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

Abstract

Background The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) with rimegepant 75 mg over 52-weeks. Methods Eligible subjects were adults with ≥1 year history of migraine and ≥ 6 MMD at baseline, who used rimegepant 75 mg up to once daily PRN (at their discretion) for up to 52-weeks in an open-label safety study (BHV3000–201; NCT03266588). Mean MMD were calculated at each 4-week period, along with mean monthly tablets taken. Migraine-specific quality of life (MSQv2) data were mapped to EQ-5D utilities and used to characterize HRQoL over time. A published network meta-analysis was used to characterize pain hours as well as time periods spent migraine free. Results One thousand forty four subjects were included in this post-hoc analysis. Overall mean MMD were 10.9 at baseline and decreased to 8.9 by week 52. Tablet use remained stable over the follow-up period. A total of 0.08 incremental QALYs were associated with rimegepant use. Conclusion For subjects with 6 or more MMD, acute treatment of migraine attacks with rimegepant 75 mg on a PRN basis over one-year of follow-up was found to be associated with reduced MMD frequency without an increase in monthly tablet utilization, and improved HRQoL. There was no evidence of medication-related increases in MMDs when rimegepant 75 mg was used as needed for the acute treatment of migraine over 52-weeks. Trial registration ClinicalTrials.gov identifier NCT03266588.

Efficacy and safety of eptinezumab as migraine preventive therapy: A systematic review and meta-analysis

“…The most common side effects are nasopharyngitis, upper respiratory tract infection, sinusitis, and influenza. In this trial, three participants were pregnant during the intervention period, two of whom miscarried (Kudrow et al, 2021). This report is in line with the results of our meta-analysis.…”

“…A study shows that those with more frequent MMD have a lower quality of life, lower productivity, and a high burden of maintenance costs (Johnston et al, 2022). Our meta-analysis showed that the administration of eptinezumab decreased the mean MMD.…”

Is the right way to go in between?

“…It would be difficult to modulate monoclonal antibody concentrations on a relevant time scale but this can readily be done for gepants. This is what the study of Johnston et al reports [ 15 ]. Modulation of CGRP blocking was instantiated by the need for taking 75 mg of rimegepant for acute treatment, and the authors’ analysis could show that this patient-determined practice is associated with a long-term reduction in monthly migraine days that seems to be of similar effect size as the overall preventive effect of 75 mg of rimegepant taken every other day (QOD) in the pivotal study by Croop et al [ 10 ].…”

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale

“…In the USA, migraine is estimated to cost the economy US$19 billion a year. Each of the currently available CGRP-targeted mAbs and gepants have demonstrated improvement in functional and quality-of-life assessments (e.g., MIDAS, headache impact test (HIT-6), and health-related quality of life (HRQoL) [ 84 , 107 , 117 , 144 – 147 ].…”